Leu-Enkephalin
An endogenous opioid pentapeptide that binds delta and mu opioid receptors to modulate pain signaling and immune activity.
Leucine enkephalin (Leu-enkephalin; Tyr-Gly-Gly-Phe-Leu) is an endogenous opioid pentapeptide derived from proenkephalin A, co-discovered by John Hughes and Hans Kosterlitz in 1975 alongside methionine enkephalin as the first endogenous ligands identified for opiate receptors in the mammalian brain. It binds preferentially to delta opioid receptors and to a lesser extent mu receptors, producing analgesic effects and modulating pain transmission at spinal and supraspinal levels including the periaqueductal gray. Exogenous use faces fundamental pharmacological barriers — a very short plasma half-life, near-complete first-pass peptidase metabolism, and poor blood-brain barrier penetration — which have prevented its clinical development and kept it a research-only tool compound.
Class
Endogenous opioid pentapeptide
Half-life
Very short — seconds to minutes in plasma due to rapid peptidase degradation
Routes
Subcutaneous, Intranasal
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Pain modulation
Acts as an endogenous analgesic by binding delta and mu opioid receptors, modulating pain signal transmission in dorsal horn neurons and at supraspinal sites including the periaqueductal gray. Rodent pharmacology has established its antinociceptive role in descending pain-modulation pathways.
Anti-inflammatory activity
Activation of opioid receptors on immune cells is associated with anti-inflammatory effects, a research area documented in preclinical opioid-peptide literature.
Immune modulation
Binds opioid receptors expressed on immune cells, influencing cytokine production and immune cell trafficking, which underlies its investigation as an immune-modulating peptide.
Mechanism
How it works
Leu-enkephalin is cleaved from the precursor protein proenkephalin A and functions as an endogenous ligand at opioid receptors. It binds preferentially to delta opioid receptors and, to a lesser extent, mu opioid receptors in both the central nervous system and the periphery.
In pain processing, the peptide modulates signal transmission in dorsal horn neurons of the spinal cord and acts at supraspinal sites — notably the periaqueductal gray and medullary reticular formation — that form part of the descending pain-modulation system. Delta-receptor agonism at these sites produces dose-dependent antinociception through mechanisms that are pharmacologically distinct from mu opioid receptor ligands.
Beyond the nervous system, leu-enkephalin activates opioid receptors expressed on immune cells, where it can influence cytokine production and immune cell trafficking — the basis for its study as an anti-inflammatory and immune-modulating agent.
As an exogenous compound it is limited by a very short plasma half-life (seconds to minutes), near-complete first-pass metabolism by peptidases, and poor blood-brain barrier penetration. These barriers have prevented its development as a systemic analgesic and explain the absence of human therapeutic trials.
Evidence
Research & clinical studies (1)
Comparison of the antinociceptive action of mu and delta opioid receptor ligands in the periaqueductal gray matter, medial and paramedial ventral medulla in the rat
Intracerebral microinjection in rats showed that delta opioid receptor agonists including a leu-enkephalin analog (DADL) produced dose-dependent antinociception in the periaqueductal gray and maximal blockade of spinally mediated pain responses in the medullary reticular formation via mechanisms distinct from mu opioid receptor ligands.
PMID 2871901Safety
Side effects & considerations
Contraindications & cautions
- Cardiovascular condition
- Pregnant or nursing
Moderate risk profile in research contexts. As with any opioid-receptor ligand, caution is warranted. No systematic human safety data exist because leu-enkephalin has not been studied in human therapeutic trials. Review all reported considerations carefully before use.
FAQ
Leu-Enkephalin — common questions
What is Leu-Enkephalin?
Leucine enkephalin (Leu-enkephalin; Tyr-Gly-Gly-Phe-Leu) is an endogenous opioid pentapeptide derived from proenkephalin A, co-discovered by John Hughes and Hans Kosterlitz in 1975 alongside methionine enkephalin as the first endogenous ligands identified for opiate receptors in the mammalian brain. It binds preferentially to delta opioid receptors and to a lesser extent mu receptors, producing analgesic effects and modulating pain signal transmission at spinal and supraspinal levels including the periaqueductal gray.
What is Leu-Enkephalin primarily studied for?
Its main research areas are pain modulation, anti-inflammatory activity, and immune modulation.
What are the reported benefits of Leu-Enkephalin?
Research primarily documents effects related to pain modulation, anti-inflammatory activity, and immune modulation. These are areas covered in preclinical literature — individual response varies and effects depend on context of use.
What does the research show about Leu-Enkephalin?
Research in rats using intracerebral microinjection found that delta opioid receptor agonists including leu-enkephalin analogs (DADL) produced dose-dependent antinociceptive effects in the periaqueductal gray and maximal blockade of spinally mediated pain responses in the medullary reticular formation, via mechanisms distinct from mu opioid receptor ligands.
Why is Leu-Enkephalin not used as a drug?
Exogenous leu-enkephalin faces fundamental pharmacological barriers — a very short plasma half-life (seconds to minutes), near-complete first-pass metabolism by peptidases, and poor blood-brain barrier penetration — which have prevented its clinical development as an analgesic and explain the absence of human therapeutic trials.
What are the side effects of Leu-Enkephalin?
Reported contraindications and considerations include cardiovascular condition and being pregnant or nursing. It carries a moderate research risk profile; consult a qualified healthcare professional before use.
